CLAIMS

1) An ophthalmic composition comprising hyaluronic acid and arabinogalactan in synergistic amounts for use in the treatment of dry-eye syndrome.

2) An ophthalmic composition comprising hyaluronic acid and arabinogalactan in synergistic amounts according to claim 1, for use in the treatment of dry-eye syndrome, accompanied by the inflammatory phenomena related to the action of the enzyme system xanthine dehydrogenase/xanthine oxidase, which are reduced due to the combined and synergistic action of the two active ingredients hyaluronic acid and arabinogalactan.

3) An ophthalmic composition according to claim 1 or 2, further comprising panthenol, trehalose and vitamin E-D-α-polyethylene glycol (TGPS), for use in the treatment of dry-eye syndrome, accompanied by the inflammatory phenomena related to the action of the enzyme system xanthine dehydrogenase/xanthine oxidase.

4) ~~An~~ The ophthalmic composition for use according to any one of claims 1 to 3, characterized in that the hyaluronic acid amount ranges from 0.15% to 0.4% by weight, on the total weight.

5) ~~An~~ The ophthalmic composition for use according to any one of claims 1 to 3, characterized in that the arabinogalactan amount ranges from 0.40% to 1.00% by weight, on the total weight.

6) ~~An~~ The ophthalmic composition for use according to claim 3, characterized in that the panthenol amount ranges from 0.30% to 0.60% by weight, on the total weight.

7) ~~An~~ The ophthalmic composition for use according to claim 3, characterized in that the trehalose amount ranges from 3.00% to 4.00% by weight, on the total weight.

8) ~~An~~ The ophthalmic composition for use according to claim 3, characterized in that the vitamin E-D-α-polyethylene glycol (TGPS) amount is comprised between 0.030% to 0.050% by weight, on the total weight.

9) ~~An~~ The ophthalmic composition for use according to claim 3, characterized in that it is filterable and sterilizable at 0.2 microns.

10) ~~An~~ The ophthalmic composition for use according to claim 1 or 3, further comprising one or more additional therapeutic agents, selected from the group comprising growth factors, anti-inflammatory agents, vitamins, fibronectin and collagen, amino acids and/or pharmacologically acceptable substances for the treatment of dry-eye syndrome, accompanied by the inflammatory phenomena related to the action of the enzyme system xanthine dehydrogenase/xanthine oxidase.

11) ~~An~~ The ophthalmic composition for use according to claim 3, further comprising a gelling agent such as Poloxamer 407, in a range of concentrations between 1% and 9% by weight.

12) ~~Use of a hyaluronic acid and arabinogalactan association~~ A method of preparing an eye drop comprising both hyaluronic acid and arabinogalactan, suitable for the treatment of dry-eye syndrome, in synergistic amounts, for preparing, after sterilization by filtration, an ophthalmic product for topical use in

the form of eye drops for the treatment of dry-eye syndrome.

13) Use of a composition comprising a hyaluronic acid and arabinogalactan association, further comprising panthenol, trehalose, and vitamin E-D-α-polyethylene glycol (TGPS), for producing eye drops for the treatment of dry-eye syndrome, after sterilization by filtration.

14) Use of a composition comprising a hyaluronic acid and arabinogalactan association, further comprising panthenol, trehalose, and vitamin E-D-α-polyethylene glycol (TGPS), with the addition of a gelling agent, such as Poloxamer 407, for producing a gel for the treatment of dry-eye syndrome.

15) Use of a composition comprising hyaluronic acid, arabinogalactan, panthenol, trehalose and vitamin E-D-α-polyethylene glycol (TGPS), for preparing eye drops or a gel for the treatment of dry-eye syndrome, accompanied by the inflammatory phenomena related to the action of the enzyme system xanthine dehydrogenase/xanthine oxidase.